A Coruna

• A Phase 3, randomized, double-blind, placebo-controlled, multicenter study of IV FDY-5301 in patients with a myocardial infarction (STEMI) Ended
  2024-514372-40-00 5 2022-04-12 Anterior ST-Elevation Myocardial Infarction
• "OPAL Master Protocol Phase 1B/2 Multicohort Umbrella Study to Evaluate the Safety and Efficacy of Novel Treatments and/or Combinations of T … Ended
  2023-505097-16-00 4 2022-04-04 Ovarian Neoplasms
• Predicting olaparib sensitivity in metastatic HER2-negative breast cancer with BRCA1, BRCA2, PALB2, RAD51C or RAD51D mutation or RAD51-negat … Ended
  2024-511875-14-00 4 2022-03-24 Pre and post-menopausal women and men with unresectable locally advanc
• A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults with Familial Chylomicronemia Syndrome Ended
  2024-514336-24-00 5 2022-03-24 Familial Chylomicronemia Syndrome (FCS)
• ​Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination with Chemotherapy Versus Pembrolizumab Plus Chemotherapy as Fir … Ended
  2023-506074-12-00 5 2022-03-22 Metastatic Non-Small Cell Lung Cancer
• A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia. Ended
  2024-510696-38-00 5 2022-03-08 Severe Hypertriglyceridemia.
• CO-THEIA (COMBINATION THERAPY WITH METHOTREXATE AND ADALIMUMAB FOR UVEITIS): EFFICACY, SAFETY AND COST-EFFECTIVENESS OF METHOTREXATE, ADALIM … Ended
  2024-513123-17-00 5 2022-01-12 Non-infection uveitis
• Randomised, double-blind, placebo-controlled, active-treatment clinical trial to assess the analgesic efficacy and safety of an oral combina … Ended
  2024-517807-35-00 5 2022-01-10 Moderate to severe somatic pain.
• A clinical trial with nadunolimab in combination with gemcitabine plus carboplatin in patients with advanced triple negative breast cancer. … Ended
  2024-512052-38-00 9 2021-12-02 Advanced triple negative breast cancer
• A Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis Ended
  2023-509782-20-00 4 2021-11-11 Diffuse Cutaneous Systemic Sclerosis
• Study of efficacy, safety and tolerability of DFV890 in patients with knee osteoarthritis Ended
  2023-507559-30-00 4 2021-11-09 Knee Osteoarthritis
• The BURAN Study of Buparlisib (AN2025) In Combination with Paclitaxel Compared to Paclitaxel Alone, in Patients with Recurrent or Metastatic … Ended
  2024-517251-12-00 5 2021-11-02 Recurrent or metastatic head and neck squamous cell carcinoma
• A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) Ended
  2022-500881-80-00 5 2021-10-29 Chronic Heart Failure With Reduced Ejection Fraction
• A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Naive Su … Ended
  2024-512142-42-00 5 2021-10-05 Psoriatic Arthritis
• A continuation study to evaluate the prophylactic and on demand treatment of congenital Thrombotic Thrombocytopenic Purpura (cTTP) with the … Ended
  2024-513839-24-00 5 2021-09-07 Congenital Thrombotic thrombocytopenic purpura (cTTP)
• Study of efficacy, safety, and tolerability of LNA043 in patients with symptomatic knee osteoarthritis Ended
  2023-509937-37-00 4 2021-07-21 Osteoarthritis
• A phase III trial of trastuzumab + ALpelisib +/- fulvestrant versus trastuzumab + chemotherapy in patients with PIK3CA mutated previously tr … Ended
  2024-514611-98-00 5 2021-07-20 PIK3CA mutated HER2+ advanced or relapsed breast cancer (BC) previousl
• DTG/3TC vs BIC/FTC/TAF maintenance therapy in people living with HIV: an open-label randomized clinical trial Ended
  2024-515167-56-00 11 2021-06-22 HIV
• Study of Atezolizumab plus chemotherapy plus chemo-radiotherapy and Atezolizumab maintenance therapy in non-resectable non-small cell lung c … Ended
  2024-514803-33-00 4 2021-06-16 Non-small cell lung cancer (NSCLC)
• A randomized, 2-arm, open-label, phase II study of abemaciclib combined with endocrine therapy (letrozole or fulvestrant) with or without a … Ended
  2023-509591-42-00 4 2021-05-04 HR-positive/HER2-negative breast cancer
• A study to investigate the novel agent BNT111 and cemiplimab in combination or as single agents in patients with advanced melanoma that has … Ended
  2023-509513-36-00 4 2021-03-24 Melanoma (Stage III and IV)
• “A Multicentric, Open-Label, Single Arm Phase II Study To Evaluate The Efficacy And Safety Of The Combination Of PEmbrolizumab And Lenvatini … Ended
  2023-508001-25-00 4 2021-03-15 Metastatic Thymic Carcinoma & B3-thymoma.
• A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Experien … Ended
  2023-507415-35-00 5 2021-01-15 Psoriatic Arthritis
• Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants wit … Ended
  2023-508443-40-00 5 2020-12-18 Lung Cancer, Non-Small Cell

Showing 505–528 of 558 trials